Marksans Pharma Limited announced on July 3, 2026, the outcome of its board meeting, confirming the recommendation of a final dividend of ₹0.90 per equity share of face value ₹1 each for the financial year ended March 31, 2026. The announcement was made to the NSE under ISIN INE750C01026.

Dividend Details

The board meeting outcome was communicated to the exchange at 12:02 PM on July 3, 2026. The original dividend recommendation had been made at a separate board meeting held on May 26, 2026, as disclosed to the exchange at that time.

Dividend Growth Trend

Marksans Pharma has demonstrated a consistent and steep upward trajectory in dividend payouts over the past decade. The per-share payout history reveals the scale of this expansion:

The company paid no dividend in FY21 and FY22 prior to reinstating the payout at ₹0.25 per share in FY22. Since FY22, the dividend has grown at a compounded annual rate of approximately 37.8% over four years, rising from ₹0.25 to ₹0.90. Over the full period since FY17, the per-share payout has expanded 18 times, from ₹0.05 to ₹0.90.

Dividend Yield Context

Since the quote data was not available at the time of publication, the dividend yield cannot be precisely calculated. However, investors tracking the stock against its 52-week range and prevailing market price should note that at a hypothetical price of ₹200 per share, the ₹0.90 dividend would imply a yield of approximately 0.45%, which is broadly in line with pharmaceutical sector peers that typically prioritise capital appreciation over high yield payouts. Investors should verify the current market price on NSE to derive the precise yield applicable to their cost of acquisition.

Company Background

Marksans Pharma is a Mumbai-based pharmaceutical manufacturer with a significant presence in regulated markets including the United States, the United Kingdom, and Europe. The company focuses primarily on over-the-counter and generic formulations. Its consistent dividend growth over recent years aligns with improved profitability and cash flow generation reported across FY23 to FY26.

What It Means for Investors

The 12.5% increase in the per-share dividend from FY25 to FY26 signals continued earnings confidence from the board. The unbroken streak of annual dividend increases since FY22, combined with the absence of any dividend cut in that period, reflects a maturing capital return policy. Shareholders of record as of the record date to be announced will be eligible to receive the ₹0.90 per share payout upon AGM approval. Investors should monitor the company's announcement of the record date and AGM schedule through NSE filings for precise eligibility timelines.